REVIEW PAPER
Retroperitoneal fibrosis – a review of the literature and own experience
More details
Hide details
Online publication date: 2009-08-11
Reumatologia 2009;47(3):158-163
KEYWORDS
ABSTRACT
Retroperitoneal fibrosis (RPF) is a rare disease of unclear pathogenesis. It is characterized by the presence of a fibro-inflammatory mass usually surrounding the abdominal aorta and the iliac arteries. Early diagnosis and appropriate treatment is crucial in order to avoid severe complications. This review summarizes the actual knowledge on RPF. We also propose a treatment algorithm based on the available literature and our own experience.
REFERENCES (46)
1.
Koep L, Zuidema GD. The clinical significance of retroperitoneal fibrosis. Surgery 1977; 81: 250-257. .
2.
ter Maaten JC, Smith AJ, Gans RO. Idiopathic retroperitoneal fibrosis: idiopathic or secondary to atherosclerosis? Neth J Med 2000; 56: 35-37. .
3.
Parums DV. The spectrum of chronic periaortitis. Histopathology 1990; 16: 423-431. .
4.
Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006; 367: 241-251. .
5.
Uibu T, Oksa P, Auvinen A, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet 2004; 363: 1422-1426. .
6.
Meier P, Gilabert C, Burnier M, Blanc E. La fibrose retropéritonéale, une maladie inflammatoire méconnue. Observations clinique et revue de la littérature. Nephrologie 2003; 24: 173-180. .
7.
van Bommel EF. Retroperitoneal fibrosis. Neth J Med 2002; 60: 231-242. .
8.
Baker LR, Mallinson WJ, Gregory MC, et al. Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol 1987; 60: 497-503. .
9.
Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoproteins and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990; 114: 383-387. .
10.
Gilkeson GS, Allen NB. Retroperitoneal fibrosis. A true connective tissue disease. Rheum Dis Clin North Am 1996; 22: 23-38. .
11.
Vaglio A, Corradi D, Manenti L, et al. Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med 2003; 114: 454-462. .
12.
Martorana D, Vaglio A, Greco P, et al. Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. Arthritis Rheum 2006; 55: 126-130. .
13.
Mitchinson MJ. Aortic disease in idiopathic retroperitoneal and mediastinal fibrosis. J Clin Pathol 1972; 25: 287-293. .
14.
Vaglio A, Greco P, Corradi D, et al. Autoimmune aspects of chronic periaortitis. Autoimmun Rev 2006; 5: 458-464. .
15.
Agarwal P, Fahn S, Frucht SJ. Diagnosis and management of pergolid-induced fibrosis. Mov Disord 2004; 19: 699-704. .
16.
Ahmad S. Methyldopa and retroperitoneal fibrosis. Am Heart J 1983; 105: 1037-1038. .
17.
Waters VV. Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: case report. J Urol 1989; 141: 936-937. .
18.
Demko TM, Diamond JR, Groff J. Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations. J Am Soc Nephrol 1997; 8: 684-688. .
19.
Thomas MH, Chisholm GD. Retroperitoneal fibrosis associated with malignant disease. Br J Cancer 1973; 28: 453-458. .
20.
Seth A, Ansari MS, Trikha V, Mittal R. Retroperitoneal fibrosis: a rare complication of Pott’s disease. J Urol 2001; 166: 622-623. .
21.
Moul JW. Retroperitoneal fibrosis following radiotherapy for stage I testicular seminoma. J Urol 1992; 147: 124-126. .
22.
Wilson MC, Berry AR, McNair TJ, Thomson JW. Obstructive uropathy after pan-proctocolectomy for ulcerative colitis. Gut 1980; 21: 808-809. .
23.
Jois RN, Gaffney K, Marshall T, Scott DG. Chronic periaortitis. Rheumatology (Oxford) 2004; 43: 1441-1446. .
24.
Kottra JJ, Dunnick NR. Retroperitoneal fibrosis. Radiol Clin North Am 1996; 34: 1259-1275. .
25.
Warnatz K, Keskin AG, Uhl M, et al. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005; 64: 828-833. .
26.
Yamada H, Komatsu R, Nagae H, et al. Idiopathic retroperitoneal fibrosis with duodenal obstruction successfully treated with corticosteroids. Intern Med 1998; 37: 592-598. .
27.
Vaglio A, Manetti L, Allegri L, et al. ANCA-positive periaortic vasculitis: does it fall within the spectrum of vasculitis? J Intern Med 2002; 251: 268-271. .
28.
Mulligan SA, Holley HC, Koehler RE, et al. CT and MRI imaging in the evaluation of retroperitoneal fibrosis. J Comput Assist Tomogr 1989; 13: 277-281. .
29.
Chander S, Ergun EL, Chugani HT, et al. High 2-deoxy-2-[18F]-fluoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumor. Mol Imaging Biol 2002; 4: 363-368. .
30.
Salvarani C, Pipitone N, Versari A, et al. Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum 2005; 53: 298-303. .
31.
Vaglio A, Versari A, Fraternali A, et al. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of idiopathic retroperitoneal fibrosis. Arthritis Rheum 2005; 53: 122-125. .
32.
Vaglio A, Greco P, Versari A, et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent “scar”? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol 2005; 23: 231-234. .
33.
Wagenknecht LV, Hardy JC. Value of various treatments for retroperitoneal fibrosis. Eur Urol 1981; 7: 193-200. .
34.
Ilie CP, Pemberton RJ, Tolley DA. Idiopathic retroperitoneal fibrosis: the case for nonsurgical treatment. BJU Int 2006; 98: 137-140. .
35.
Maillart E, Laueriére L, Kassis S, et al. Peut-on proposer une prise en charge de la fibrose rétropéritonéale idiopathique validée par les données de la literature. Rev Med Interne 2006; 27: 854-857. .
36.
Heidenreich A, Derakhshani P, Neubauer S, Krug B. Treatment outcomes in primary and secondary retroperitoneal fibrosis. Urologe A 2000; 39: 141-148. .
37.
Harreby M, Bilde T, Helin P, et al. Retroperitoneal fibrosis treated with methylprednisolone pulse and disease-modifying antirheumatic drugs. Scand J Urol Nephrol 1994; 28: 237-242. .
38.
Marcolongo R, Tavolini IM, Laveder F, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 2004; 116: 194-197. .
39.
Scavalli AS, Spadaro A, Riccieri V, et al. Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. Clin Rheumatol 1995; 14: 481-484. .
40.
Marzano A, Trapani A, Leone N, et al. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis 2001; 60: 427-428. .
41.
Grotz W, von Zedtwitz I, Andre M, Schollmeyer P. Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids. Lancet 1998; 352: 1195. .
42.
Tönshoff B. The current status of mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 1999; 3: 5-9. .
43.
Fry AC, Singh S, Gunda SS, et al. Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Nephron Clin Pract 2008; 108: c213-c220. .
44.
Loffeld RJ, van Weel TF. Tamoxifen for retroperitoneal fibrosis. Lancet 1993; 341: 382. .
45.
van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006; 144: 101-106. .
46.
Tralce L, Antonelli A, Dotti P, Cunico SC. Epidemiology, clinical features and treatment of idiopathic retroperitoneal fibrosis: our experience. Arch Ital Urol Androl 2004; 76: 135-139.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.